Objective The reliability and validity of generic utility measures have not yet been summarized in people with multiple sclerosis (MS). It is important to assess the psychometric properties of these measures, to ensure that the values obtained by the scoring system are valid for interpretation and utilization by clinicians, researchers and policy makers. Therefore, the objective of this review was to summarize the evidence from published literature on the psychometric properties of generic utility measures in MS. Methods A structured literature search was conducted by using multiple electronic databases. All potentially relevant abstracts and full-text articles were read to identify publications that may be eligible for inclusion in the review. A meta-analysis was conducted to combine correlation coefficient values for convergent validity. The Schmidt-Hunter method, a weighted mean of the correlation coefficient values, was used. Heterogeneity, the percentage of total variation across studies that is due to between-study differences rather than chance, was assessed using the I 2 statistic. Results The following generic utility measures were identified: the EQ-5D (n = 9)/EQ-5D-5 Level (EQ-5D-5L) (n = 1), followed by the Health Utilities Index Mark 3/2 (HUI2/HUI3) (n = 3), the SF-6D (n = 2), the Assessment of Quality of Life (AQOL) (n = 2), and the Quality of Well-Being (QWB) scale (n = 1). Ceiling and floor effects were present for the EQ-5D and the SF-6D, but not for the HUI3. The EQ-5D, the SF-6D and the HUI3 demonstrated excellent reliability. In terms of discriminative ability, the SF-6D and the QWB scale were not able to differentiate between moderately and severely disabled MS patients, and the EQ-5D was not able to differentiate between those who were mildly and moderately disabled. The AQOL and the HUI3, on the other hand, demonstrated good discriminative ability, as both measures were able to differentiate between all levels of disability. As for convergent validity, the HUI2/HUI3 were highly correlated (r = 0.7) against measurement instruments that evaluated impairments such as disease severity, ambulation and manual dexterity. The EQ-5D, SF-6D and the QWB scale demonstrated small to moderate correlations (r = 0.4) against instruments evaluating impairments, and slightly stronger correlations against measures of activity limitations/participation restrictions and health-related quality of life (HRQL) (r = 0.6). Conclusion To our knowledge this is the first study to review the validity and reliability of generic utility measures in MS. The HUI3 demonstrated the strongest psychometric properties when compared with other utility measures. However, the HUI3 only measures impairment and excludes important components of HRQL such as participation restrictions. The EQ-5D, the SF-6D and the QWB scale, on the other hand, do include items on participation. However, these measures demonstrated a lack of content validity in MS by missing certain domains that were important to the disease, as well as difficulty in differentiating between different levels of disability. The PharmacoEconomics (2014) 32:759-773 DOI 10.1007 addition of MS-specific 'bolt-ons' to generic utility measures and the development of an MS specific utility measure are possible areas of exploration for future research.
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Introduction
Health care has a dual aim of improving quality of life and extending life expectancy. The quality-adjusted life-year (QALY) was developed to capture both of these goals. When making decisions on whether an intervention should be made available within a health care system, policy makers are often interested in the cost per QALY associated with an intervention. Generic utility measures or preference-based measures, such as the EQ-5D [1, 2] and the SF-6D [3] , are usually administered on patients to capture the 'Q' in the QALY.
The assumption underlying generic utility measures is that they can make comparisons across all types of diseases and interventions. This assumption has been proven to be true for many health conditions, where these measures have passed psychometric tests of reliability and validity [4] [5] [6] [7] . However, the validity of these measures has been questioned for other health conditions [8] [9] [10] [11] . For example, the mobility domain of the EQ-5D consists of three response levels: 'I have no problems walking about' or 'I have some problems in walking about' or 'I am confined to bed'. The response option 'I have some problems in walking about' covers a wide range of gait disability, as it is the only level between 'no problems' and 'confined to bed'. In a study involving both patients with stroke and multiple sclerosis (MS) [12] , those who reported having 'moderate' problems walking about had varying levels of function. Patients' mobility ranged from those who used a cane occasionally in public, through to those who were confined to a wheelchair most of the time but could still transfer from the wheelchair to their bed.
Furthermore, ceiling effects and floor effects have also been reported for these measures [13] [14] [15] . Brazier et al. [15] compared the SF-6D and the EQ-5D in seven different patient populations, namely low back pain, chronic obstructive pulmonary disease, irritable bowel syndrome, leg ulcer, menopausal women and osteoporosis. The EQ-5D had a larger percentage of the participants in the top category of each dimension compared with the SF-6D (i.e., 17-72 % for the EQ-5D compared with 4-35 % for the SF-6D). Conversely, the SF-6D had a larger proportion of the participants on the lowest level of physical functioning and role limitation than did the EQ-5D on mobility and usual activities (i.e., 25 and 38 % for the SF-6D vs. 0.2 and 10.5 % for the EQ-5D).
MS is a chronic, demyelinating disease of the central nervous system that has a significant impact on patients' level of functioning and disability [16] . It is associated with a variety of health-related problems such as fatigue, muscle weakness, altered sensation, limitations in carrying out daily activities and restrictions with participation in life roles. The reliability and validity of generic utility measures have not yet been summarized in this population. It is important to assess the psychometric properties of these measures, to ensure that the values obtained by the scoring system are valid for interpretation and utilization by clinicians, researchers and policy makers [17] . Generic utility measures that do not have good psychometric properties may result in a false estimate of QALYs and bias the evaluation of the cost effectiveness of different interventions in MS.
Therefore, the objective of this review was to summarize the evidence from published literature on the psychometric properties of generic utility measures in MS.
Methods
We conducted a structured search to identify all possible articles that provided information on the psychometric properties of generic utility measures in MS. 
Study Selection
All potentially relevant abstracts were read to identify publications that could be eligible for inclusion in the review. Full-text articles of the selected abstracts were retrieved and selected based on the following inclusion/ exclusion criteria:
• Type of publication: Only studies that were published in peer-reviewed journals were included. Conference proceedings and abstracts were excluded.
• Language: Only studies published in English or French were considered. • Study design: All types of study designs were included.
• Study population: Studies that included persons diagnosed with possible or definite MS were included in the review without restrictions for disease severity, sex, type of MS or the presence of medical co-morbidities.
• Type of outcome measure: studies that reported on the psychometric properties of one or more of the following utility measures were included: the Quality of WellBeing (QWB) scale [18, 19] , the Health Utilities Index Mark 2 (HUI2) [20, 21] , the Health Utilities Index Mark 3 (HUI3) [21, 22] , the 15D [23, 24] , the EQ-5D/ EQ-5D-5 Level (EQ-5D-5L) [1, 2] , the Assessment of Quality of Life (AQOL) [25, 26] and the SF-6D [3] . The key characteristics of each of these measures are provided in Table 1 .
• Psychometric properties: Studies that provided potentially relevant information on the psychometric property of a utility measure, whether this was their objective or not, were included in the review.
Data Extraction
The following information was extracted from each study: study characteristics (country, study design, and quality assessment of the study), subject characteristics (sample size, age and disease severity), outcome measures and results of psychometric tests.
Quality Assessment of Studies
The quality of the full-text articles included for review was assessed with a 13-item critical appraisal tool that was developed to assess psychometric properties of clinical measures [27] . Of the 13 items, four of the items were uniquely for articles assessing reliability, four were only for validity studies, and the remaining five items were for either one. The 13 items were scored as 'yes', 'no' or 'not applicable'. The Scottish Intercollegiate Guidelines Network Methodology (2013) was used to provide an overall summary of the level of evidence for each study: (i) two pluses '??' were given when all or most of the quality criteria were fulfilled; (ii) one plus '?' when some of the criteria were fulfilled; and (iii) a minus '-' when few or none of the criteria were fulfilled. Therefore, '??' indicated that the study was of high quality, '?' indicated that it was of moderate quality, and '-' that it was of low quality.
Methodological quality was assessed only for studies whose primary or secondary objectives were to evaluate the psychometric property of a utility measure. If a study's objective was not to evaluate the psychometric property of a utility measure, its methodological quality was not assessed.
Psychometric Properties
The following psychometric properties were assessed from the included articles:
• Content validity: the extent to which the content of an instrument is an adequate reflection of the construct being measured. It evaluates whether all items included in a measure are relevant for the study population or disease [28] .
• Convergent validity: considered a subtype of construct validity. It is the extent to which measures of constructs that theoretically should be related to each other are, in fact, observed to be related to each other [29] .
• Discriminative validity (known-groups validity): considered a subtype of construct validity. It is the degree to which an instrument can demonstrate different scores for groups known to vary or differ on the variables being measured [29] .
• Responsiveness: the ability of a measure to detect change over time in the construct being measured [28] .
• Test-retest reliability: the extent to which a measure provides the same results on repeated trials, assuming that the characteristics being measured do not change [29] .
• Floor/ceiling effect: the percentage of the sample obtaining the worst and best possible scores. Values [15 % were indicative of a floor or ceiling effect [30] .
Quantitative Analysis of Studies (Meta-Analysis)
The extent to which generic utility measures correlated with other measures of (i) impairment, (ii) activity limitations/participation restrictions, and (iii) health-related quality of life (HRQL) was examined to evaluate convergent validity. Forest plots were drawn to combine the correlation coefficient values. The Schmidt-Hunter method, which is a weighted mean of the correlation coefficient values, was used. This method is based on a random-effects model that weights each study by its sample size. Pooled correlation values of 0.1-0.3 were considered small, 0.4-0.6 were considered medium, and [0.7 were considered large [31] . Heterogeneity, the percentage of total variation across studies that is due to between-study differences rather than chance, was assessed using the I 2 statistic. The I 2 ranges between 0 and 100 %, with higher values indicating greater heterogeneity. A p value of \0.05 and an I 2 value [50 % indicated significant heterogeneity. All analysis was carried out using StatsDirect [32] .
Results

Number of Articles Sourced
The study selection process is presented in Fig. 1 . A total of 337 records were identified through the database searches. Ninety-two records were removed because they were duplicates, leaving 245 abstracts for screening. Of these, 230 articles were excluded because (i) they did not include a generic utility measure, (ii) they included a generic utility measure but did not provide information on its psychometric properties, (iii) study sample was not exclusive to MS, (iv) language was not English or French, and (v) they were conference proceedings or abstracts. This left 15 fulltext articles for inclusion in the review.
One of the articles [33] included in this review (that also came up during the electronic database search) was published by the authors (AK and NM). This study reported data on the EQ-5D and the SF-6D (derived from the RAND-36) in 185 people with MS [33] . Although available, results on the convergent validity of these measures were not reported (as it was not the aim of that paper); therefore, these important data were incorporated into this review.
Brief Description of Included Studies for Each Utility Measure
The following generic utility measures were identified in the included articles: the EQ-5D (n = 9)/EQ-5D-5L (n = 1), followed by the HUI2/HUI3 (n = 3), the SF-6D (n = 2), the AQOL (n = 2), and last the QWB scale (n = 1). There were no studies that reported on the psychometric property of the 15D. Table 2 presents key characteristics for each study, and Supplementary Table 1 presents a breakdown of the methodological quality assessment (see the Electronic Supplementary Material). EQ-5D/EQ-5D-5L: There were nine studies [13, [33] [34] [35] [36] [37] [38] [39] [40] that assessed the psychometric properties of the EQ-5D, and one study [41] that assessed the EQ-5D-5L (total = 10 studies). The studies were cross-sectional in design, with sample sizes ranging from 18 to 911 and mean utility scores ranging from 0.49 to 0.80. The studies were of moderate to high quality.
HUI2: Only one study [42] provided information on the psychometric property of the HUI2. The study was crosssectional in design and consisted of 153 patients with MS who were recruited from two different MS clinics. The study was of moderate methodological quality.
HUI3: There were two studies [13, 43] that provided information on the psychometric properties of the HUI3. Both studies were cross-sectional, with sample sizes of 187 and 302. The mean utility score was presented in only one study, and was 0.57 with a 95 % confidence interval (CI) of 0.52-0.63. Methodological quality was assessed for one of the studies [13] and was graded as high quality. The remaining study [43] was not assessed for methodological quality because its primary objective was not to test psychometric property of the HUI3. SF-6D: Two studies [13, 33] reported on the psychometric properties of the SF-6D. Both studies were crosssectional in design and had similar sample sizes (187 and 185). The mean utility value was reported by one of the studies, and was 0.69 standard deviation (SD) 0.13. The studies were of moderate to high quality.
AQOL: The AQOL was evaluated in two studies [44, 45] , both of which were conducted by the same author. The first study [44] consisted of a community-based MS group (n = 101) in Australia with a mean utility score of 0.46 (SD 0.25) on the AQOL. The second study [45] included a sample of 61 MS patients suffering from chronic pain with mean utility scores ranging from 0.24 to 0.37.
QWB scale: The psychometric property of the QWB scale was reported in only one study [46] , which involved 274 patients with MS. The study was cross-sectional in design and did not report the mean utility value for the sample. The methodological quality of the study was not assessed, as its primary objective was not to evaluate the psychometric property of the QWB scale.
Psychometric Properties of Identified Utility Measures
EQ-5D/EQ-5D-5L
3.3.1.1 Content Validity The content validity of the EQ-5D was evaluated in one study [33] on a sample of 185 people with MS. The objective of this study was to estimate the extent to which the EQ-5D captured domains that were relevant to patients with MS. Certain domains such as walking (mobility) and mood (anxiety/depression) which were identified by patients to be important to their quality of life were included in the EQ-5D. However, other important domains such as fatigue and cognition were not included in the utility measure.
3.3.1.2 Convergent Validity Impairment: Figure 2 is a forest plot for convergent validity of the EQ-5D tested against outcome measures of impairment, such as gait speed and disease severity. The pooled correlation coefficient for convergent validity of the EQ-5D was 0.35 (95 % CI 0.25-0.45). The I 2 statistic for heterogeneity was high at 94.6 % (p \ 0.0001).
Activity limitations/participation restrictions: Supplementary Fig. 1 presents the correlation coefficient values for convergent validity of the EQ-5D against outcome HRQL: Figure 3 presents the combined correlation value for the EQ-5D compared against measures evaluating HRQL, which was 0.56 (95 % CI 0.54-0.59). There was no heterogeneity among the included studies (I 2 statistic = 0 %, p = 0.53).
3.3.1.3 Discriminative/Known-Groups Validity Discriminant validity of the EQ-5D was evaluated in three studies [36, 37, 39] . Two of these studies [36, 39] reported that the mobility item lacked discriminative ability because patients who were wheelchair bound did not fit into any response category.
Orme et al. [37] evaluated the extent to which the EQ-5D was able to differentiate between different levels of disease severity. Disease severity was measured using the Expanded Disability Status Scale (EDSS), a classification scheme extending from 0 (normal neurological examination) to 10 (death due to MS). The authors reported that the EQ-5D was able to differentiate between all EDSS levels, except between EDSS levels 3 and 4 (utility score for EDSS 4 was higher than EDSS 3). Fisk et al. [13] found that the decline in utility scores between the mildly (EDSS 0-2.5) and moderately (EDSS 3.0-5.5) impaired MS patients was not statistically significant (p = 0.30).
Only one study [41] evaluated the discriminative capacity of the EQ-5D-5L, which showed a linear decline in utility scores from EDSS 0-6, after which point the relationship exhibited greater variability. Furthermore, the discriminative power of the EQ-5D-5L was considerably lower for the domains of self-care and anxiety/depression, compared with the other domains (mobility, pain and usual activities).
Test-Retest Reliability
The intra-class correlation coefficient for test-retest reliability of the EQ-5D was 0.81 [13] .
3.3.1.5 Floor/Ceiling Effect For the EQ-5D, ceiling effects were reported for the mobility item (32 %) and the self-care item (68 %) [13] . No floor effects were found for any of the EQ-5D items. As for the EQ-5D-5L [41] , ceiling effects were reported for the self-care item (64 %) and the anxiety/depression item (46 %).
HUI2
3.3.2.1 Content Validity One study [33] evaluated the content validity of the HUI2. The authors identified that the utility measure included domains relevant to patients with MS, such as cognition. However, the authors also identified that the HUI2 was missing certain domains such as fatigue and work.
Convergent
Validity Impairment: One study [42] calculated the correlation between the EDSS and the HUI2 to be 0.54 (p \ 0.0001). 
Discriminative/Known-Groups
Validity Mean HUI2 utility scores were 0.83, 0.84, 0.71, 0.71, 0.62 and 0.59 for EDSS levels 1-6, respectively [42] .
Floor/Ceiling Effect
There were no studies that reported on the presence or absence of floor/ceiling effects in the HUI2.
Test-Retest Reliability
There were no studies that reported about test-retest reliability of the HUI2.
HUI3
3.3.3.1 Content Validity Two studies [33, 43] provided information on the content validity of the HUI3. In the first study, the authors identified that important domains such as fatigue were missing in the HUI3. Furthermore, the HUI3 included domains that were not relevant to many patients with MS, such as self-care, vision and hearing. This may not only affect the measure's ability to detect meaningful change, but may also result in an overestimation of utility scores and false estimates of QALYs. For the second study [43] , clinically important differences in scores between patients with MS and the general population were observed for ambulation, pain, dexterity and cognition. However, differences were not observed for hearing and speech, suggesting that these domains or items may not be impacted in MS.
Convergent Validity
Impairment: When the convergent validity of the HUI3 was tested against outcome measures of impairments, the pooled correlation value was 0.73 (95 % CI 0.68-0.77). The I 2 statistic for heterogeneity was 55 % (p = 0.082) (Fig. 4) .
Activity limitations/participation restrictions and HRQL: There were no studies that assessed the convergent validity of the HUI3 against measures of activity limitation and participation restrictions, or HRQL.
Discriminative/Known-Groups Validity
The HUI3 demonstrated known-groups validity by being able to differentiate between mildly, moderately and severely disabled MS patients [13] .
Test-Retest Reliability
The intra-class correlation coefficient for test-retest reliability of the HUI3 was 0.87 [13] .
3.3.3.5 Floor/Ceiling Effect There were no ceiling or floor effects for the HUI3 [13] . Only 3 % of subjects obtained a utility score of 1.0 and 10 % of subjects obtained a utility score of \0.
SF-6D
3.3.4.1 Content Validity Only one study [33] reported on the content validity of the SF-6D in MS. The SF-6D was found to include several domains that were important to the quality of life of patients with MS, such as work, fatigue, sports (vigorous physical activities) and social life. However, it was missing important domains such as walking and cognition.
Convergent
Validity Impairment: The pooled correlation value for convergent validity of the SF-6D against outcome measures evaluating impairments of body structure and function (Fig. 5) was 0.39 (95 % CI 0.32-0.46). The I 2 statistic was 66 % (p = 0.003). Activity limitations/participation restrictions: The combined correlation value for the SF-6D against measures evaluating activity limitations and participation restrictions was 0.57 (95 % 0.54-0.59) with an I 2 statistics of 0 % (p = 0.67) (Supplementary Fig. 2) .
HRQL: When compared against measures evaluating HRQL, the pooled correlation value for convergent validity of the SF-6D was 0.62 (95 % CI 0.50-0.73). The I 2 statistic for heterogeneity was 86 % (p = 0.008) (Fig. 6). 3.3.4.3 Discriminative/Known-Groups Validity One study [13] evaluated the discriminative ability of the SF-6D and found that although the index was able to differentiate between mildly and moderately disabled patients, it was unable to differentiate between the more severe patient groups. A flattening of utility scores beyond moderate disability was observed.
Test-Retest Reliability
The intra-class correlation coefficient for test-retest reliability of the SF-6D was 0.83 [13] .
Floor/Ceiling Effect
For the SF-6D, only 3 and 1 % of subjects reported the lowest and highest possible index scores respectively. However, floor effects were identified for the physical function subscale (41 %) and the role limitation subscale (16 %). Ceiling effects were reported for bodily pain (29 %), social function (39 %), mental health (58 %) and role limitations (84 %) [13] .
3.3.5 AQOL 3.3.5.1 Content Validity There were no studies that reported on the content validity of the AQOL in MS.
Convergent Validity
There were no studies that reported on the convergent validity of the AQOL in MS.
3.3.5.3 Discriminative/Known-Groups Validity The AQOL was able to differentiate between mildly, moderately and severely disabled patients [44] , and it was also able to differentiate between patients with different levels of pain intensity [45] .
Test-Retest Reliability
There were no studies that reported on the test-retest reliability of the AQOL.
3.3.5.5 Floor/Ceiling Effect There were no studies that reported on floor or ceiling effects.
3.3.6 QWB Scale 3.3.6.1 Content Validity There were no studies identified that reported on the content validity of the QWB scale in MS. HRQL: There were no studies that evaluated the convergent validity of the QWB scale against measures of quality of life. 3.3.6.3 Discriminative/Known-Groups Validity The QWB scale was able to discriminate between mild and moderate levels of disability, but was not able to differentiate between moderate and severe [46] .
There were no studies that reported on the test-retest reliability of the QWB scale.
3.3.6.5 Floor/Ceiling Effect There were no studies that reported on floor or ceiling effects.
Discussion
This structured review summarizing the published literature on the reliability and validity of generic utility measures in MS showed that each of the utility measures had their strengths and weaknesses. In terms of content validity, cognition, a domain important to MS, was missing in both the EQ-5D and the SF-6D. Fatigue, another important domain, was missing in the HUI and the EQ-5D. The content validity of the QWB scale and the AQOL were not assessed in any of the included studies. However, if one were to quickly review the items included in these measures, fatigue is missing in the AQOL and the QWB scale, and cognition is missing in the AQOL.
Ceiling and floor effects were present for the EQ-5D and the SF-6D, but not for the HUI3. As for test-retest reliability, the EQ-5D, the SF-6D and the HUI3 all demonstrated excellent reliability. Ceiling/floor effects and testretest reliability were not assessed for the AQOL or the QWB scale.
In terms of discriminative ability, the SF-6D and the QWB scale were not able to differentiate between moderately and severely disabled MS patients, and the EQ-5D was not able to differentiate between those who were mildly and moderately disabled. Issues were also identified with the mobility item of the EQ-5D, because patients who were wheelchair bound did not fit into any of the response categories. The AQOL and the HUI3 demonstrated good discriminative ability, as both measures were able to differentiate between all levels of disability.
As for convergent validity, the HUI3 was highly correlated (r = 0.7) against measurement instruments that evaluated impairments such as disease severity, ambulation and manual dexterity. This is probably not surprising, as the HUI3 was developed with the intention of including only impairment-related domains, and excluding 'out of skin' domains such as participation in life roles (i.e., work) [20, 21] . Impairments can impact on participation, but this association is often surprisingly weak in people with disabling health conditions as people learn to create a life even with impairments [47, 48] . In the context of MS, it is relevant to know both the level of impairment and the level to which it restricts participation [47] .
The correlations for convergent validity were very similar between the EQ-5D and the SF-6D. Both measures had small to moderate correlations (r = 0.4) against instruments evaluating impairments, and slightly stronger correlations against measures of activity limitations/participation restrictions (r = 0.6). There is considerable overlap between the EQ-5D and the SF-6D in terms of item or domain coverage. For example, both the EQ-5D and the SF-6D include an item on pain. Self-care in the EQ-5D is covered as bathing and dressing in the SF-6D. Furthermore, the equivalent of the anxiety/depression item in the EQ-5D is feeling tense and downhearted in the SF-6D.
The QWB scale behaved similarly to the EQ-5D and the SF-6D, also demonstrating small to moderate correlations (r = 0.36) with measures of impairment and activity limitations/participation restrictions (r = 0.55). The QWB scale contains items that are similar to the EQ-5D and the SF-6D (mobility, physical activity, social activity, plus 27 symptoms). Although the QWB scale was the first utility measure to be developed, it is used to a lesser extent than the other utility measures. This may be because it requires substantial training of interviewers and detailed probing of the patient [49] . A more recent self-administered version of the QWB scale has been developed [50] ; however, it still takes about 14 min to complete [51] . The EQ-5D and the SF-6D, on the other hand, require only 5 min or less to complete.
To our knowledge this is the first study that reviewed the validity and reliability of generic utility measures in MS. Structured reviews similar to ours have been conducted for other health conditions, such as urinary incontinence [52] , spinal cord injury [53] , visual disorders [54] , schizophrenia [11] , diabetes [5] and cardiovascular disease [4] . The results of these studies were mixed, where some reviews found evidence that supported the use of generic utility measures for the health condition under study [4, 5, 52] , while others were not able to make such conclusions [11, 53] .
There were limitations in the included studies that need to be acknowledged. First, several of the included studies were not specifically designed to test the psychometric properties of utility measures; they provided data that were potentially relevant for this review. Second, the high levels of heterogeneity among the included studies indicate that the pooled correlation coefficients for convergent validity should be interpreted with caution. Third, a full assessment of the psychometric property of the AQOL or the QWB scale was not possible, as we were not able to find information on test-retest reliability and presence of floor or ceiling effects. Fourth, our findings showed that the psychometric property of the 15D in MS has not yet been evaluated; therefore, an analysis of the appropriateness of this utility measure in MS could not be made. Fifth, there were no studies that assessed the responsiveness of these utility measures, making it difficult to draw any conclusions on the ability of these measures to detect clinically important change.
The generic utility measures identified in this review were able to explain only 36 % (r = 0.6) of the variance in generic and disease-specific health profiles such as the Patient Generated Index (PGI) and the Patient-Reported Indices for MS (PRIMUS). A large of proportion of the variance (64 %) remained unexplained in these measures, which raises the question of whether generic utility measures are indeed providing an adequate representation of patients' HRQL. Although items that are commonly included in generic measures are also of importance to people with MS, generic utility measures may miss certain domains that are important or specific to the disease. The addition of disease specific 'bolt-ons' or 'dimension extensions' to generic utility measures is one possible method to improve the validity of these measures in MS. A recent review by Lin et al. [55] identified several domains that were specific to different diseases and that could be used as 'bolt-ons' to the EQ-5D. Potential domains that could be included as 'bolt-ons' to generic utility measures are cognition (not found in the EQ-5D or SF-6D) and fatigue (not included in the EQ-5D or HUI2/3). With the bolt-on approach, the wording or phrasing of the bolt-on item and its response options first needs to be developed. Following this, a valuation exercise with the bolt-on item is carried out and a multi-attribute utility function or scoring algorithm calculated. The challenge with the bolt-on approach is that the addition of a new domain may have an impact on the way people value the original dimensions, altering the original regression coefficient values.
Another possible solution to tackle the limitations found with generic utility measures is to develop a disease-specific utility measure for MS. Such a measure would include only domains that are relevant to people with MS and, therefore, provide an accurate assessment of the clinical and cost effectiveness of different treatment options in this population. One of the concerns with disease-specific measures is that they may not be able to capture the impact of co-morbid medical conditions on HRQL. However, in the context of MS, the age of diagnosis is approximately 20-40 years, when co-morbidities are rare. As the context of use for a condition-specific measure is around medication that is usually prescribed around time of diagnosis, most patients will not have co-morbidities. These develop late on with aging, as in any group of people.
As each disease-specific measure will have a different classification system, a concern is whether this will affect comparison of treatments across diseases. However, the issue of comparability is not just limited to the context of disease-specific utility measures but also applies to generic utility measures. As pointed out in this review, there are considerable differences in content coverage (i.e., domains) and methods of valuation (i.e., standard gamble vs. time trade-off vs. VAS) among the generic measures. Furthermore, studies have shown that there are significant discrepancies in utility scores obtained using the EQ-5D, HUI3 and the SF-6D for the same medical condition [9] . For this reason, in the UK, the National Institute of Health and Care Excellence (NICE) advocates for the use of one descriptive system, namely the EQ-5D, for economic evaluation purposes. However, the limitation with this approach is that one measure may not be appropriate for all health conditions. In Canada, the Canadian Agency for Drugs and Technologies in Health (CADTH) does not have a preference for any one utility measure. Provided that the utility measure is reliable and demonstrates validity in the population of interest, it may be used for economic evaluation purposes.
Conclusion
The HUI3 demonstrated the strongest psychometric properties when compared with other utility measures. However, the HUI3 only measured impairment and excluded important components of HRQL, such as activity limitations and participation restrictions. The EQ-5D, the SF-6D and the QWB scale, on the other hand, did include items on participation in life roles. However, these measures demonstrated a lack of content validity in MS by missing certain domains that were important to the disease, as well as difficulty in differentiating between different levels of disability. The addition of MS-specific 'bolt-ons' to generic utility measures and the development of an MS specific utility measure are possible areas of exploration for future research.
